Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
← catalyst calendarNCT07746895 · readout in 1,960 d
Sponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →. With IQVIA Pty Ltd.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
150estimated
Sites
101
Countries
Australia, Austria, Belgium +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-09 | estimated | When the study began enrolling |
| Primary completion | 2031-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- C3 Glomerulopathy (C3G)
- Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Intervention
- Drug: Pegcetacoplan
Primary outcome
what the primary-completion date above is the date OFAchieving urine protein-to-creatinine ratio (UPCR) of <1 g/g
measured at 6 months after starting pegcetacoplan treatment
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed